Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Yanqiao Zhang et al.|Clinical Cancer Research|2021Cited by 119
Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trialDan Liu, Lin Shen, Jun Zhou et al.|BMC Medicine|2022Cited by 84
Supplementary Data 2 from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Wei Jia et al.|Unknown|2023Cited by 0
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Wei Jia et al.|Unknown|2023Cited by 0
Data from Camrelizumab Combined with Chemotherapy Followed by Camrelizumab plus Apatinib as First-line Therapy for Advanced Gastric or Gastroesophageal Junction AdenocarcinomaZhi Peng, Lin Shen, Wei Jia et al.|Unknown|2023Cited by 0